Bernard Rubin

4.4k total citations · 2 hit papers
63 papers, 3.6k citations indexed

About

Bernard Rubin is a scholar working on Molecular Biology, Rheumatology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Bernard Rubin has authored 63 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 14 papers in Rheumatology and 13 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Bernard Rubin's work include Systemic Lupus Erythematosus Research (11 papers), Renin-Angiotensin System Studies (11 papers) and Protein Hydrolysis and Bioactive Peptides (10 papers). Bernard Rubin is often cited by papers focused on Systemic Lupus Erythematosus Research (11 papers), Renin-Angiotensin System Studies (11 papers) and Protein Hydrolysis and Bioactive Peptides (10 papers). Bernard Rubin collaborates with scholars based in United States, Malaysia and Sweden. Bernard Rubin's co-authors include Miguel A. Ondetti, David W. Cushman, Jens F. Rehfeld, F. Stadil, Michael J. Antonaccio, Robert J. Laffan, Zola P. Horovitz, Thomas Schaeffer, John C. Burke and M.E. Goldberg and has published in prestigious journals such as Nature, Science and SHILAP Revista de lepidopterología.

In The Last Decade

Bernard Rubin

59 papers receiving 3.1k citations

Hit Papers

Design of Specific Inhibitors of Angiotensin-Converting E... 1972 2026 1990 2008 1977 1972 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents
    1977 1.5k citations Bernard Rubin, David W. Cushman et al. profile →
  2. Production and Evaluation of Antibodies for the Radioimmunoassay of Gastrin
    1972 396 citations Jens F. Rehfeld, F. Stadil et al. Scandinavian Journal of Clinical and Laboratory Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernard Rubin United States 24 2.0k 998 833 431 391 63 3.6k
Joseph R. Kahn United States 27 1.8k 0.9× 1.3k 1.3× 287 0.3× 224 0.5× 548 1.4× 39 3.2k
Huy Ong Canada 37 2.0k 1.0× 783 0.8× 387 0.5× 249 0.6× 528 1.4× 140 4.4k
Hitoshi Miyazaki Japan 35 2.2k 1.1× 1.0k 1.0× 225 0.3× 154 0.4× 568 1.5× 162 4.4k
Peter Brecher United States 44 2.8k 1.4× 1.2k 1.2× 175 0.2× 352 0.8× 722 1.8× 113 5.4k
F. Merlin Bumpus United States 43 3.3k 1.6× 4.2k 4.2× 703 0.8× 257 0.6× 1.9k 4.9× 163 7.6k
Rayudu Gopalakrishna United States 29 2.5k 1.2× 239 0.2× 445 0.5× 345 0.8× 159 0.4× 82 4.3k
T. Y. Shen United States 26 1.5k 0.8× 284 0.3× 350 0.4× 185 0.4× 180 0.5× 63 3.9k
Herman Van Belle Belgium 30 1.4k 0.7× 404 0.4× 380 0.5× 92 0.2× 342 0.9× 86 3.2k
Maurice Wibo Belgium 27 2.3k 1.2× 381 0.4× 313 0.4× 182 0.4× 241 0.6× 67 3.9k
F.A. Fitzpatrick United States 41 1.8k 0.9× 303 0.3× 212 0.3× 368 0.9× 209 0.5× 99 4.9k

Countries citing papers authored by Bernard Rubin

Since Specialization
Citations

This map shows the geographic impact of Bernard Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Rubin more than expected).

Fields of papers citing papers by Bernard Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Rubin. The network helps show where Bernard Rubin may publish in the future.

Co-authorship network of co-authors of Bernard Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Rubin. A scholar is included among the top collaborators of Bernard Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Rubin. Bernard Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jupe, Eldon R., Bruce Wang, Gerald H. Lushington, et al.. (2025). Impact of a digital platform and flare risk blood biomarker index on lupus: A study protocol design for evaluating self efficacy and disease management. Contemporary Clinical Trials Communications. 45. 101471–101471.
2.
Nair, Shantikumar V., et al.. (2025). Prediction of Lupus Classification Criteria via Generative AI Medical Record Profiling. BioTech. 14(1). 15–15. 2 indexed citations
3.
4.
5.
Worley, Karen, Scott Milligan, & Bernard Rubin. (2023). Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data. Lupus Science & Medicine. 10(2). e001024–e001024. 5 indexed citations
6.
Bell, Christopher F., Ming Kei Chung, & Bernard Rubin. (2023). Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and Therapy. 10(2). 447–462. 2 indexed citations
7.
8.
Bell, Christopher F., Maral DerSarkissian, Guillaume Germain, et al.. (2022). A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA. Rheumatology and Therapy. 10(1). 261–274. 1 indexed citations
9.
Namas, Rajaie, et al.. (2015). Embolic Stroke as the Initial Manifestation of Systemic Lupus Erythematosus. SHILAP Revista de lepidopterología. 2015. 1–5. 4 indexed citations
10.
Waldron, Thomas L., et al.. (1989). Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme. Journal of Cardiovascular Pharmacology. 13(6). 887–894. 29 indexed citations
11.
Waldron, Thomas L., et al.. (1989). Fosinopril, a Phosphinic Acid Inhibitor of Angiotensin I Converting Enzyme: In Vitro and Preclinical In Vivo Pharmacology. Journal of Cardiovascular Pharmacology. 14(5). 730–736. 37 indexed citations
12.
Rubin, Bernard, Luc Reininger, Marie Suzan, et al.. (1984). On the Molecular Basis of T Helper Cell Function. Scandinavian Journal of Immunology. 19(6). 563–573. 8 indexed citations
13.
Antonaccio, Michael J., et al.. (1981). Effects of captopril on vascular reactivity of SHR in vivo and in vitro.. Hypertension. 3(6_pt_2). II–211. 27 indexed citations
14.
Rubin, Bernard, et al.. (1979). Development of specific inhibitors of angiotensin I converting enzyme (kininase II).. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(13). 2778–82. 39 indexed citations
15.
Rubin, Bernard. (1972). Studies on the Induction of Antibody Synthesis against Sulfanilic Acid in Rabbits.. Scandinavian Journal of Immunology. 1(2). 135–141. 8 indexed citations
16.
Rehfeld, Jens F., F. Stadil, & Bernard Rubin. (1972). Production and Evaluation of Antibodies for the Radioimmunoassay of Gastrin. Scandinavian Journal of Clinical and Laboratory Investigation. 30(2). 221–232. 396 indexed citations breakdown →
17.
Rubin, Bernard, John Krapcho, & John P. High. (1966). Analgesic and antiserotonin activities of SQ 10,643 [cinanserin HCI, 2′ -(3-dimethylaminopropylthio)cinnamanilide HCI] and related compounds. Life Sciences. 5(9). 845–851. 4 indexed citations
18.
Rubin, Bernard, Joseph J. Piala, John C. Burke, & Bradford N. Craver. (1964). A NEW, POTENT AND SPECIFIC SEROTONIN INHIBITOR, (SQ 10,643) 2'-(3-DIMETHYLAMINOPROPYLTHIO) CINNAMANILIDE HYDROCHLORIDE: ANTISEROTONIN ACTIVITY ON UTERUS AND ON GASTROINTESTINAL, VASCULAR, AND RESPIRATORY SYSTEMS OF ANIMALS.. PubMed. 152. 132–43. 49 indexed citations
19.
Rubin, Bernard & John C. Burke. (1953). ABSORPTION, DISTRIBUTION AND EXCRETION OF ISONIAZID (NYDRAZID) IN THE DOG. Journal of Pharmacology and Experimental Therapeutics. 107(2). 219–224. 12 indexed citations
20.
Rubin, Bernard & John C. Burke. (1952). BIOASSAY OF VERATRUM VIRIDE. I. EFFECT OF VERGITRYL ON CAROTID SINUS PRESSOR REFLEX. Journal of Pharmacology and Experimental Therapeutics. 105(4). 409–420. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph R. Kahn Breakdown of academic impact, for papers by Huy Ong Breakdown of academic impact, for papers by Hitoshi Miyazaki Breakdown of academic impact, for papers by Peter Brecher Breakdown of academic impact, for papers by F. Merlin Bumpus Breakdown of academic impact, for papers by Rayudu Gopalakrishna Breakdown of academic impact, for papers by T. Y. Shen Breakdown of academic impact, for papers by Herman Van Belle Breakdown of academic impact, for papers by Maurice Wibo Breakdown of academic impact, for papers by F.A. Fitzpatrick
Rankless by CCL
2026